Bio-rad Laboratories, Inc. · NYSE:BIO
Bio-rad Laboratories — Q1 2026 Earnings Presentation
18 slides from Bio-rad Laboratories's earnings presentation, Apr 30, 2026
Slide 1: First Quarter 2026 Financial Results
First Quarter 2026 Financial Results Supplemental Earnings Results Presentation April 30, 2026
Slide 2: Safe Harbor
Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future
Slide 3: Our Mission is to advance science and save lives, together
Our Mission is to advance science and save lives, together
Slide 4: Q1 2026 GAAP Financial Results
Q1 2026 GAAP Financial Results Operating Net Cash From Revenue Gross Margin Operations Margin $592M 52.3% 5.8% $108M Change +1.1% Flat +180 bps -$22M YoY -4.2% CN* * Currency-Neutral Revenue: We report percentage sales growth/decline in currency-neutral amounts by calculating translated prior period
Slide 5: Q1 2026 Non-GAAP Financial Results
Q1 2026 Non-GAAP* Financial Results Gross Operating Free Cash Revenue Margin* Margin* Flow* $592M 53.1% 6.6% $78M Change +1.1% -70 bps -420 bps -$17M YoY -4.2% CN** * Reconciliations to the comparable GAAP measure for the non-GAAP items shown above are detailed in the reconciliation table in Bio-Rad
Slide 6: Q1 2026 Business Segment Revenue and Geographic Mix
Q1 2026 Business Segment Revenue and Geographic Mix Revenue by Business Segment Revenue by Region Life Science 39% APAC 19% Americas 46% $592M $592M Clinical Diagnostics 61% EMEA 35% 6
Slide 7: Life Science Segment
Life Science Segment Geographic Revenue Mix APAC 21% Q1 2026 Revenue Americas 46% $229M Flat YoY EMEA 33% -4.3% YoY CN * Product Revenue Mix Process Chrom • Segment CN* results primarily driven by ongoing Double Digit YoY challenges in the academic research market, CN Decline particularly in the Ame
Slide 8: Clinical Diagnostics Segment
Clinical Diagnostics Segment Geographic Revenue Mix Q1 2026 Revenue APAC 17% $364M +1.9% YoY Americas 47% -4.1% YoY CN * • Segment CN* results driven by the recent EMEA 36% escalation of regional conflicts in the Middle East • CN* revenue decreased primarily in EMEA 8 * Currency-Neutral Revenue: We
Slide 9: Balance Sheet Highlights
Balance Sheet Highlights March 31, December 31, (In $ millions) 2026 2025 Cash & Short-Term $1,565 $1,541 Investments Long-Term Debt, including current maturities $1,203 $1,203 Inventories, net $771 $741 Investment in Sartorius AG $4,901 $5,669 9
Slide 10: Updating Full-Year 2026 Outlook
Updating Full-Year 2026 Outlook Current Prior Revenue CN* YoY Growth -3.0% to +0.5% +0.5% to +1.5% Life Science Revenue CN* YoY -3.0% to -1.0% 0.0% to +0.5% Clinical Diagnostics Revenue CN* YoY -3.0% to +1.0% +1.0% to +2.0% Non-GAAP Gross Margin** 53.0% to 54.0% 54.0% to 54.5% Non-GAAP Operating Mar
Slide 11: Appendix
Appendix
Slide 12: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures 12
Slide 13: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures 13
Slide 14: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued) 14
Slide 15: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued) 15
Slide 16: Explanations of Non-GAAP Adjustments
Explanations of Non-GAAP Adjustments 16
Slide 17: Other Key Metrics
Other Key Metrics Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The company also uses this measure as a
Slide 18: 2026 Financial Outlook
2026 Financial Outlook Forecasted non-GAAP operating margin excludes 89 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, eff